How Indirect Are The Legitimate Costs Of Doing Science?

"What we will hear today is a story of taxpayer dollars going to bloated overhead rather than to scientific research. It is a story of excess and arrogance, compounded by lax governmental oversight." Rep. John D. Dingell (D-Mich.) thus opened a March 13 congressional hearing investigating alleged misuses of indirect costs reimbursements by Stanford University. In the two months since that hearing, payment of indirect costs has become a matter of public debate, not to mention public ridicule.

Written byJulia King
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

"What we will hear today is a story of taxpayer dollars going to bloated overhead rather than to scientific research. It is a story of excess and arrogance, compounded by lax governmental oversight." Rep. John D. Dingell (D-Mich.) thus opened a March 13 congressional hearing investigating alleged misuses of indirect costs reimbursements by Stanford University.

In the two months since that hearing, payment of indirect costs has become a matter of public debate, not to mention public ridicule. These costs--a university's expenses for maintaining its physical plant, its personnel, its library, and other services that support research--are tacked onto individual grants. Reminiscent of the Defense Department's payment of hundreds of dollars for replacement toilet seats, the Stanford case in particular, and the indirect costs issue in general, have come to be perceived as a new high in bureaucratic bumbling, as well as the frittering away of scarce government resources.

Not ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies